Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
N/A
1(25.0%)
4Total
Phase 1(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06830863Phase 1Recruiting

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

Role: lead

NCT06137157Phase 1Recruiting

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

Role: lead

NCT04731259Phase 1Withdrawn

Study to Evaluate the Safety of ATR-04

Role: lead

NCT03820076Not ApplicableCompleted

Safety Study of AZT-04 for Cosmetic Use

Role: lead

All 4 trials loaded